Sorry, you need to enable JavaScript to visit this website.
Pfizer Oncology
Loading...

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

CD228 and 4-1BB-directed Antibody-Anticalin® Bispecific Protein

Geo Regions

Important Notice Regarding the Scientific Information You Have Requested

You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven. 

Please acknowledge that you understand this before proceeding.

CD228 and 4-1BB-directed Antibody-Anticalin® Bispecific Protein

PF-08046049 is an investigational compound. Its safety and efficacy have not been established

Share to an HCP

Overview + Rationale

  • PF-08046049 is an investigational costimulatory bispecific molecule composed of a CD228-directed antibody and 4-1BB-directed Anticalin® proteins designed to provide a costimulatory bridge between tumor-reactive cytotoxic T cells and CD228-expressing tumor cells1
  • PF-08046049 targets CD228 (melanotransferrin), which has minimal expression in normal tissue and is selectively expressed by multiple tumor types including melanoma, non-small cell lung cancer, colorectal cancer, pancreatic cancer, and mesothelioma1,2
  • 4-1BB is an inducible costimulatory immune receptor expressed on activated T cells and other immune cell populations3,4

Mechanism of Action

PF-08046049

Stage of Development

Melanoma

Advanced Melanoma

Phase 1 Monotherapy*
This information is current as of August 5th 2025.

*Closed to Enrollment. This program was discontinued but the study is still open (not recruiting) and patients still on study are in follow up.

Anticalin® is a registered US trademark of Pieris Pharmaceuticals Gmbh.

REFERENCES:  1. Updegraff B. SITC 2022. Poster 1201; 2. Sandall SL. Cancer Res. 2019;79: Abstract 2688; 3. Vinay DS. Mol Cancer Ther. 2012:1062-70; 4. Bartkowiak T. Front Oncol: 2015:117; 5. Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT05571839 Accessed July 7, 2025.